ACE INHIBITORS ARE RATIONAL PHARMACOTHERAPY OF ENDOTHELIAL DYSFUNCTION
https://doi.org/10.20996/1819-6446-2008-4-2-89-92
Abstract
Aim. To study effects of ACE inhibitor perindopril on markers of endothelial dysfunction in therapy of patients with arterial hypertension (HT).
Material and methods. 82 patients with HT, complicated by ischemic stroke were involved in the study. 30 patients with uncomplicated HT were included into control group. Antihypertensive therapy with perindopril (52 patients) or amlodipine (30 patients) was conducted additionally to standard neurotropic therapy in hypertensive patients with ischemic stroke. Phase-contrast microscopy and enzyme immunoassay were used for screening of endothelial dysfunction markers (blebbing, desquamated endothelial cells, membrane-liberated parts, sPECAM-1).
Results. Reduction in levels of markers of endothelial dysfunction was observed among patients treated with perindopril in comparison with patients who did not receive ACE inhibitor or patients of control group. Target levels of blood pressure were reached in 96% of patients treated with perindopril. Сonclusion. ACE inhibitors in therapy patients with HT reduce endothelial dysfunction additionally to antihypertensive effect.
About the Authors
M. P. Metrova
Krasnoyarsk State Medical Academy
Russian Federation
Department of Therapy for out-patient clinic and Family Medicine
Russian Federation
Department of Therapy for out-patient clinic and Family Medicine
A. B. Salmina
Krasnoyarsk State Medical Academy
Russian Federation
Department of Biochemistry
Russian Federation
Department of Biochemistry
A. I. Inzhutova
Krasnoyarsk State Medical Academy
Russian Federation
Department of Biochemistry
Russian Federation
Department of Biochemistry
O. S. Bahmeteva
Krasnoyarsk State Medical Academy
Russian Federation
Department of Biochemistry
Russian Federation
Department of Biochemistry
References
1. Гороховская Г.Н., Петина М.М., Акатова Е.В. и др. Возможности коррекции эндотелиальной дисфункции ингибиторами ангиотен- зинпревращающего фермента. Consilium medicum 2005;2 (приложение):3-7.
2. Гомазков О.A. Система эндотелиновых пептидов: механизмы кардио-васкулярных патологий. Вопр мед хим 1999;(4):5-8.
3. Инжутова А.И. Клеточно-гуморальные характеристики патологи- ческого процесса осложненных форм гипертонической болезни. Сибирский медицинский журнал 2006;21(1 приложение):46-7.
4. Инжутова А.И., Салмина А.Б., Петрова М.М. и др. Регистрация блеббинга плазматической мембраны лимфоцитов периферической крови как экспресс-метод оценки тяжести состояния больных осложненными формами гипертонической болезни. Бюлл СО РАМН 2007;(1):6-10.
5. Казачкина С.С., Лупанов В.П., Балахонова Т.В. Функция эндотелия при ишемической болезни сердца и атеросклерозе и влияние на нее различных сердечно-сосудистых препаратов. Сердечная недостаточность 2003;4(6):315-6.
6. Карпов Ю.А. Ингибиторы ангиотензинпревращающего фермента и лечение артериальной гипертонии: современный подход. Кардиология 2002;(4):23-6.
7. Симоненко В.Б., Широков Е.А. Основы кардионеврологии. М.: Медицина; 2001.
8. Bell D.M., Johns T.E., Lopez L.M. Endothelial dysfunction: implications for the therapy of cardiovascular diseases. Ann Pharmacoter 1998;32:459-470.
9. Huot J., Houle F., Rousseau S. et al. SAPK2/p38-dependent F-actin reorganization regulates early membrane blebbing during stress-induced apoptosis. J Cell Biol 1998;143(5):1361-73.
10. Lind L, Granstam SO, Millgard J. Endothelium-dependent vasodilatation in hypertension – review. Blood Press 2000;9:4-15.
Review
For citations:
Metrova M.P., Salmina A.B., Inzhutova A.I., Bahmeteva O.S. ACE INHIBITORS ARE RATIONAL PHARMACOTHERAPY OF ENDOTHELIAL DYSFUNCTION. Rational Pharmacotherapy in Cardiology. 2008;4(2):89-92. (In Russ.) https://doi.org/10.20996/1819-6446-2008-4-2-89-92
Views:
815
Email this article 